I can speak a bit in terms of price.
As you're likely aware, the only federal lever that is able to exert any authority over price of patented medicines in Canada is the Patented Medicine Prices Review Board. I'm sure I answered a question related to the modernization effort from one of your colleagues when we were last here. They have authority under the Patent Act and its regulations to set what are termed “non-excessive prices” for patented medicines, and they do that based on the regulatory tools that are available to them.
That being said, as I'm sure you're also aware, Canada pays some of the highest prices in the world for patented medicines. We're third among the OECD countries, so it is acknowledged that prices of patented medicines in Canada are high.
The only other mechanism to bring prices down for Canadians is through negotiating mechanisms, largely through the pan-Canadian Pharmaceutical Alliance. That, as you're aware, negotiates prices for Canada's public drug plans. Prices would only be negotiated for those drugs that have received a positive recommendation for a formulary listing from the Canadian Agency for Drugs and Technologies in Health, better known as CADTH. That would not necessarily apply to all of the drugs that you're speaking about.